India's Supreme Court has rejected a request by Swiss drug-maker Novartis to patent an updated version of its cancer drug Glivec.
Glivec costs around 2,000 euros per month whereas the domestically produced generic equivalent costs around 140 euros.
The judgement is supported by healthcare activists who want the government to make medicines cheaper.
...
No Comment | euronews: watch the international news without commentary | http://www.euronews.net/nocomment/